Dechra
Dechra Pharmaceuticals PLC, commonly known as Dechra, is a leading global veterinary pharmaceutical company headquartered in the United Kingdom. Founded in 1997, Dechra has established a strong presence in Europe, North America, and Australia, focusing on the development and marketing of high-quality products for companion animals and livestock. Specialising in veterinary medicines, Dechra offers a diverse range of core products, including anaesthetics, dermatology treatments, and nutritional supplements. What sets Dechra apart is its commitment to innovation and quality, ensuring that its products meet the highest standards of safety and efficacy. With a robust market position, Dechra has achieved significant milestones, including numerous product launches and strategic acquisitions, solidifying its reputation as a trusted partner in animal health. The company continues to lead the way in veterinary pharmaceuticals, dedicated to improving the health and well-being of animals worldwide.
DitchCarbon Score
How does Dechra's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dechra's score of 54 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Dechra's reported carbon emissions
In 2022, Dechra Pharmaceuticals, headquartered in Great Britain, reported total greenhouse gas emissions of approximately 14,375,000 kg CO2e globally. This includes 6,709,000 kg CO2e from Scope 1 (direct emissions), 4,896,000 kg CO2e from Scope 2 (indirect emissions from energy use), and 2,770,000 kg CO2e from Scope 3 (indirect emissions from the value chain). In the UK, the company’s emissions were about 1,241,000 kg CO2e, with 489,757 kg CO2e from Scope 1, 607,104 kg CO2e from Scope 2, and 144,040 kg CO2e from Scope 3. Dechra has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 GHG emissions by 42% by 2030 from a 2021 baseline. Additionally, the company targets a 51.6% reduction in Scope 3 emissions per GBP value added within the same timeframe. Long-term goals include achieving net-zero emissions across the value chain by 2050, with a further reduction of 90% in Scope 1 and 2 emissions and 97% in Scope 3 emissions per GBP value added by the same year. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect Dechra's commitment to addressing climate change and reducing its carbon footprint in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 6,747,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 4,969,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 2,347,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dechra is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
